ONC-006
Oncology
PreclinicalActive
Key Facts
About RapaFusyn Pharmaceuticals
RapaFusyn Pharmaceuticals is a private, preclinical-stage biotech based in San Diego, founded in 2018. The company has developed a proprietary platform to create RapaGlues, a unique modality of non-degrading molecular glues that harness the FKBP12 chaperone to target intractable proteins. With a pipeline of eight disclosed programs across oncology and immunology & inflammation, the company is advancing its lead program towards IND and recently secured a significant $44 million Series A financing to fuel its platform and pipeline development.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |